News Cancer biotech Nouscom adds €120m, and other financings A €120m Series D for Swiss biotech Nouscom will support trials of a Lynch syndrome vaccine, with Soufflé, Estuary, and Microbiotica also raising cash.
News UK spin-out Microbiotica wants to be world leader in microbi... Spin-out will exploit Sanger Institute expertise
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.